

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>ASTEX THERAPEUTICS LIMITED</td> <td>03/12/2010</td> </tr> <tr> <td>THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL</td> <td>03/29/2010</td> </tr> </tbody> </table>		Name	Execution Date	ASTEX THERAPEUTICS LIMITED	03/12/2010	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL	03/29/2010				
Name	Execution Date										
ASTEX THERAPEUTICS LIMITED	03/12/2010										
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL	03/29/2010										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>ASTEX THERAPEUTICS LIMITED</td> </tr> <tr> <td>Street Address:</td> <td>436 CAMBRIDGE SCIENCE PARK, MILTON ROAD</td> </tr> <tr> <td>City:</td> <td>CAMBRIDGE</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>CB4 0QA</td> </tr> </table>		Name:	ASTEX THERAPEUTICS LIMITED	Street Address:	436 CAMBRIDGE SCIENCE PARK, MILTON ROAD	City:	CAMBRIDGE	State/Country:	UNITED KINGDOM	Postal Code:	CB4 0QA
Name:	ASTEX THERAPEUTICS LIMITED										
Street Address:	436 CAMBRIDGE SCIENCE PARK, MILTON ROAD										
City:	CAMBRIDGE										
State/Country:	UNITED KINGDOM										
Postal Code:	CB4 0QA										
<table border="1"> <tr> <td>Name:</td> <td>THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL</td> </tr> <tr> <td>Street Address:</td> <td>123 OLD BROMPTON ROAD</td> </tr> <tr> <td>City:</td> <td>LONDON</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>SW7 3RP</td> </tr> </table>		Name:	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL	Street Address:	123 OLD BROMPTON ROAD	City:	LONDON	State/Country:	UNITED KINGDOM	Postal Code:	SW7 3RP
Name:	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL										
Street Address:	123 OLD BROMPTON ROAD										
City:	LONDON										
State/Country:	UNITED KINGDOM										
Postal Code:	SW7 3RP										
<table border="1"> <tr> <td>Name:</td> <td>CANCER RESEARCH TECHNOLOGY LIMITED</td> </tr> <tr> <td>Street Address:</td> <td>SARDINIA HOUSE, SARDINIA STREET</td> </tr> <tr> <td>City:</td> <td>LONDON</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>WC2A 3NL</td> </tr> </table>		Name:	CANCER RESEARCH TECHNOLOGY LIMITED	Street Address:	SARDINIA HOUSE, SARDINIA STREET	City:	LONDON	State/Country:	UNITED KINGDOM	Postal Code:	WC2A 3NL
Name:	CANCER RESEARCH TECHNOLOGY LIMITED										
Street Address:	SARDINIA HOUSE, SARDINIA STREET										
City:	LONDON										
State/Country:	UNITED KINGDOM										
Postal Code:	WC2A 3NL										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13536174</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13536174						
Property Type	Number										
Application Number:	13536174										
CORRESPONDENCE DATA											
Fax Number:											

CH \$40.00 13536174

Phone: 5184525600

Email: dcr@hrfmlaw.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Erica M. Hines, Esq.

Address Line 1: 5 Columbia Circle

Address Line 2: HESLIN ROTHENBERG FARLEY & MESITI PC

Address Line 4: Albany, NEW YORK 12203

ATTORNEY DOCKET NUMBER:

3073.006C

NAME OF SUBMITTER:

Erica M. HINES

Total Attachments: 4

source=3073006C_Assignment3_Astex & ICR to Astex ICR & CRT#page1.tif

source=3073006C_Assignment3_Astex & ICR to Astex ICR & CRT#page2.tif

source=3073006C_Assignment3_Astex & ICR to Astex ICR & CRT#page3.tif

source=3073006C_Assignment3_Astex & ICR to Astex ICR & CRT#page4.tif

ASSIGNMENT

WHEREAS, We,

ASTEX THERAPEUTICS LIMITED, having offices at 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom; and

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, having offices at 123 Old Brompton Road, London SW7 3RP, United Kingdom;

are the owners of the entire right, title and interest in certain new and useful improvements in **PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS**, and in United States Patent Application Serial Number 10/596,788, entitled **PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS**, filed with the United States Patent and Trademark Office under 35 U.S.C. § 371 on **June 23, 2006** as a national phase entry of **PCT/GB2004/005464** which has an international filing date of **December 23, 2004**, and in any and all divisions, renewals and continuations thereof, and all Letters Patent which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in the United States; and

WHEREAS, **ASTEX THERAPEUTICS LIMITED**, having offices at 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom; **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, having offices at 123 Old Brompton Road, London SW7 3RP, United Kingdom; and **CANCER RESEARCH TECHNOLOGY LIMITED**, having offices at Sardinia House, Sardinia Street, London, WC2A 3NL, United Kingdom, are desirous of obtaining the entire right, title and interest in, to and under said improvements and said Application;

NOW, THEREFORE, in exchange for good and valuable consideration, which We hereby acknowledge, We, **ASTEX THERAPEUTICS LIMITED** and **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, do hereby assign, transfer and set over, unto said **ASTEX THERAPEUTICS LIMITED**, **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, and **CANCER RESEARCH TECHNOLOGY LIMITED**, their successors, legal representatives and assigns, our entire right, title and interest in, to and under said improvements, and said Application and all divisions, renewals and continuations thereof, and all Letters Patent which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in the United States; and We hereby authorize and request the Commissioner of Patents of the United States to issue all Letters Patent for said improvements to said **ASTEX THERAPEUTICS LIMITED**, **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, and **CANCER RESEARCH TECHNOLOGY LIMITED**, their successors, legal representatives and assigns, in accordance with the terms of this instrument;

AND WE HEREBY covenant that We have full right to convey the entire interest herein assigned, and that We have not executed, and will not execute, any agreement in conflict herewith;

AND WE HEREBY grant Heslin Rothenberg Farley & Mesiti P.C. the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, **ASTEX THERAPEUTICS LIMITED** has caused this Assignment to be signed by its duly authorized representative this 12 day of March 2010 2010.

ASTEX THERAPEUTICS LIMITED

By: M. [Signature]

Title: CEO

[Signature]
Witness

[Signature]
Witness

IN TESTIMONY WHEREOF, **THE INSTITUTE OF CANCER RESEARCH; ROYAL CANCER HOSPITAL** has caused this Assignment to be signed by its duly authorized representative this ___ day of _____ 2010.

THE INSTITUTE OF CANCER RESEARCH; ROYAL CANCER HOSPITAL

By: _____

Title: _____

Witness

Witness

ASSIGNMENT

WHEREAS, We,

ASTEX THERAPEUTICS LIMITED, having offices at 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom; and

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, having offices at 123 Old Brompton Road, London SW7 3RP, United Kingdom;

are the owners of the entire right, title and interest in certain new and useful improvements in **PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS**, and in United States Patent Application Serial Number 10/596,788, entitled **PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS**, filed with the United States Patent and Trademark Office under 35 U.S.C. § 371 on **June 23, 2006** as a national phase entry of **PCT/GB2004/005464** which has an international filing date of **December 23, 2004**, and in any and all divisions, renewals and continuations thereof, and all Letters Patent which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in the United States; and

WHEREAS, **ASTEX THERAPEUTICS LIMITED**, having offices at 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom; **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, having offices at 123 Old Brompton Road, London SW7 3RP, United Kingdom; and **CANCER RESEARCH TECHNOLOGY LIMITED**, having offices at Sardinia House, Sardinia Street, London, WC2A 3NL, United Kingdom, are desirous of obtaining the entire right, title and interest in, to and under said improvements and said Application;

NOW, THEREFORE, in exchange for good and valuable consideration, which We hereby acknowledge, We, **ASTEX THERAPEUTICS LIMITED** and **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, do hereby assign, transfer and set over, unto said **ASTEX THERAPEUTICS LIMITED**, **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, and **CANCER RESEARCH TECHNOLOGY LIMITED**, their successors, legal representatives and assigns, our entire right, title and interest in, to and under said improvements, and said Application and all divisions, renewals and continuations thereof, and all Letters Patent which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said improvements in the United States; and We hereby authorize and request the Commissioner of Patents of the United States to issue all Letters Patent for said improvements to said **ASTEX THERAPEUTICS LIMITED**, **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL**, and **CANCER RESEARCH TECHNOLOGY LIMITED**, their successors, legal representatives and assigns, in accordance with the terms of this instrument;

AND WE HEREBY covenant that We have full right to convey the entire interest herein assigned, and that We have not executed, and will not execute, any agreement in conflict herewith;

AND WE HEREBY grant Heslin Rothenberg Farley & Mesiti P.C. the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, **ASTEX THERAPEUTICS LIMITED** has caused this Assignment to be signed by its duly authorized representative this ____ day of _____ 2010.

ASTEX THERAPEUTICS LIMITED

By: _____

Title: _____

Witness

Witness

IN TESTIMONY WHEREOF, **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL** has caused this Assignment to be signed by its duly authorized representative this 29th day of March 2010.

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

By: [Signature]

Title: DIRECTOR OF ENTERPRISE
SWORN BAUGHT

[Signature]
Witness

[Signature]
Witness